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Background: Skeletal muscle undergoes significant atrophy in Type 2 diabetic patients and animal models. We
aimed to determine if atrophy of Zucker rat skeletal muscle was due to the activation of intracellular damage
pathways induced by excess reactive oxygen species production (specifically those associated with the peroxidation
of lipid membranes) and calpain activity. 14 week old obese Zucker rats and littermate lean controls were injected
with 1% Evan’s Blue Dye. Animals were anaesthetised and extensor digitorum longus and soleus muscles were
dissected, snap frozen and analysed for ROS-mediated F2-isoprostane production and calpain activation/autolysis.
Contralateral muscles were histologically analysed for markers of muscle membrane permeability and atrophy.
Results: Muscle mass was lower in extensor digitorum longus and soleus of obese compared with lean animals,
concomitant with reduced fibre area. Muscles from obese rats had a higher proportional area of Evan’s Blue Dye
fluorescence, albeit this was localised to the interstitium/external sarcolemma. There were no differences in
F2-isoprostane production when expressed relative to arachidonic acid content, which was lower in the obese EDL
and soleus muscles. There were no differences in the activation of either μ-calpain or calpain-3.
Conclusions: This study highlights that atrophy of Zucker rat skeletal muscle is not related to sarcolemmal damage,
sustained hyperactivation of the calpain proteases or excessive lipid peroxidation. As such, establishing the correct
pathways involved in atrophy is highly important so as to develop more specific treatment options that target the
underlying cause. This study has eliminated two of the potential pathways theorised to be responsible.Background
Type 2 Diabetes (T2D) is a chronic lifestyle disease char-
acterised by high plasma free fatty acids (FFAs), hyper-
glycaemia, hyperinsulinaemia and insulin resistance; and
which effects multiple organ systems [1]. Notably, the
skeletal musculature undergoes significant atrophy [2],
which has further adverse impacts on disease progres-
sion. Whilst protein synthesis and degradation imbal-
ance likely accounts for this atrophy [3,4], the triggers
that lead to changes in the activation of these pathways* Correspondence: emma.rybalka@vu.edu.au
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controversial. Several catalytic pathways have been impli-
cated in atrophic cellular protein degradation including the
autophagosome-lysosomal, ubiquitin proteasome, Caspase
and Ca2+-dependent calpain pathways [5-7]. While a role
for the ubiquitin proteasome [8] and autophagosome-
lysosomal [9,10] pathways have been established in T2D-
related skeletal muscle atrophy, much less is known about
the Ca2+−dependent calpain system. Indeed, a potential
mechanism that may contribute to T2D induced muscle
degradation is via increased susceptibility of the skeletal
musculature to damage – in particular, via the flow on ef-
fects of Ca2+ dysregulation, calpain activation and sustained
free radical production, both of which are common features
of pathological muscle wasting in a variety of diseases [11].tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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proteases – skeletal muscle fibres contain both the ubi-
quitous isoforms μ-calpain, m-calpain, and calpain-10, as
well as the muscle-specific form, calpain-3 [12]. Those
calpains activated within a physiologically relevant [Ca2+]
range are calpain-3 and μ-calpain [13,14]. Calpain 3 plays
a role in remodelling and maintaining normal sarcomeric
structures, whereas μ-calpain is associated with dismant-
ling sarcomeric structures; and a balance in their activities
is important for skeletal muscle integrity (see review [15]).
Intracellular Ca2+ concentrations above resting cytosolic
levels cause autolysis of μ-Calpain and Calpain-3, thus in-
creasing their proteolytic activity [13,16]. Over-activation
of calpains due to Ca2+ overload has been implicated in
many pathological conditions including, Parkinson’s dis-
ease and muscular dystrophy [17,18]. As there is substan-
tial evidence suggesting dysregulation of intracellular Ca2+
homeostasis in T2D (for review see [19]), it is possible that
calpains are being over-activated by excessive intracellular
Ca2+ accumulation in this disease. Thus far, calpain
activity has not been investigated for a role in T2D-
associated atrophy.
Much like calcium dysregulation induces damage-
associated muscle atrophy, increases in FFA content can
lead to excessive production of reactive oxygen species
(ROS) and reduced antioxidant defences [20] resulting
in damage to proteins, lipids and nucleic acids [21].
With respect to T2D, much of the existing literature on
heightened ROS production has been restricted to the
mitochondria [22-24] and the impact on whole muscle
has not been addressed. High FFA content is also ac-
companied by changes in the lipid profile of cells which
affects membrane integrity and fluidity, as well as leaving
membranes more susceptible to ROS-induced lipid per-
oxidation further impairing their structural integrity
[25,26]. Free radical peroxidation of arachidonic acid, a
component of cell membranes, forms a prostaglandin-
like end product known as the F2-isoprostanes. Mass
spectrometry assessment of F2-isoprostanes is regarded
as the gold standard biomarker of oxidative stress (for
review see [27]) and plasma F2-isoprostanes are signifi-
cantly higher in both diabetic compared to non-diabetic
patients [28] and in obese versus lean diabetic Zucker
rats [29] T2D. F2-isoprostanes is measurable in skeletal
muscle [30], however no study to date has investigated
F2-isoprostane production in T2D skeletal muscle, and
the influence of increased oxidative stress on atrophy
and fibre morphology in this disease.
Evans Blue Dye (EBD) has been established as a useful
tool to determine cell membrane permeability and can be
assessed using different techniques including red auto-
fluorescence in tissue sections using fluorescence micros-
copy [31]. EBD binds to plasma albumin [32] and has been
used to identify damaged skeletal muscle fibres whichresults in them becoming permeable to albumin [31]. As
such, EBD would be a useful way to determine membrane
permeability and to identify potentially damaged myofi-
bres in T2D – especially given the dysregulation of cal-
cium homeostasis and potential for calpain activation, as
well as the effects of ROS and isoprostane production on
cell integrity.
Therefore, the aim of this study was to determine if
the skeletal muscle atrophy associated with obesity and
insulin-resistance in the obese rat animal model of the
disease is a result of enhanced membrane fragility medi-
ated by excess ROS and/or increased fibre damage due
to excess calpain activity, using EBD fluorescence as a
marker. We hypothesised that: (1) the sarcolemma of
obese Zucker skeletal muscle would be more permeable
to the extracellular fluid (as evidenced by albumin-
conjugated EBD fluorescence within myofibres) and
show evidence of ROS-induced lipid peroxidation (as de-
termined by F2 isoprostane production); and (2) that
increased sarcolemmal permeability would result in
hyperactivated calpains. Herein, we confirm hyperinsuli-
naemia, hyperglycaemia, reduced insulin sensitivity and
skeletal muscle atrophy in the T2D obese Zucker rat, but
importantly determine that this atrophy is not caused by
sarcolemmal damage, elevated lipid peroxidation and de-
gradative calpain activity.
Results
Weight & metabolic parameters
As expected, obese Zucker rats had significantly higher
body weights (569.0 g ± 10.8 g versus 369.7 g ± 8.0 g than
lean controls; p < 0.01). We have also confirmed hyper-
glycemia and hyperinsulinemia in the obese Zucker
model comparative to lean controls, with plasma glucose
and insulin concentrations of 271.2 ± 36.2 mg/dL versus
110.4 ± 18.2 mg/dL (p < 0.005) and 11.8 ± 0.3 μUnits/mL
versus 3.8 ± 0.7 μUnits/mL (p < 0.001), respectively
(Figure 1). Insulin resistance as determined by the
QUICKI method, was also confirmed in the obese
Zucker model with an index of 0.29 ± 0.004 compared
to 0.40 ± 0.03 in lean controls (p < 0.05; Figure 1).
Muscle atrophy
Despite their higher body weights, obese rats displayed
significantly lower skeletal muscle weights (0.132 g ±
0.003 g versus 0.167 g ± 0.004 g for lean control EDL
and 0.160 g ± 0.007 g versus 0.184 g ± 0.005 g for lean
control soleus; p < 0.01) compared to lean rats. The
lower muscle weights in the obese rats corresponded
with a 35% smaller mean fibre area in EDL (p < 0.01)
and 23% smaller fibre area in soleus (p < 0.01) compared
to lean controls (Figure 2A-C). Furthermore, fast-twitch
EDL fibres were smaller than the slow-twitch soleus
muscle fibres (p < 0.01) irrespective of animal group.
Figure 1 Plasma insulin and glucose concentration (normalised
to body weight) and relative insulin sensitivity as determined
by the quantitative insulin sensitivity check index (QUICKI) in
lean versus obese Zucker rats (n = 7). ***p < 0.001; **p < 0.005;
*p < 0.05 Lean versus Obese Zucker.
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Obese rats displayed a ~4-fold increase in the % of EBD+
to total cross sectional area in both EDL and soleus sec-
tions, compared to lean rats (Figure 3A). In addition, the
EBD+ cross sectional area was significantly greater in
soleus compared to EDL (p < 0.05). Of the fibre area
that stained EBD+, fluorescence intensity (arbitrary
fluorescence units) was significantly higher in obese
compared to lean rats for both EDL and soleus (p <
0.05) (Figure 3B). The muscle sections from obese rats
clearly showed, however, that while exhibiting a higher
proportion of EBD fluorescence compared to lean con-
trols, the dye is localised to the interstitium and not
penetrating the sarcolemma (as indicated by the solid ar-
rows Figure 3D and E) . As such, the location (intramyofi-
bre or interstitium) of EBD fluorescence within the
total muscle section was semi-quantified using a seven-
point Likert scale where 0 indicates no signal and 6
indicates very strong signal (Figure 3C). There was no
difference in the intramyofibre EBD fluorescence intensity
between lean or obese muscle, nor was there any diffe-
rence between EDL and soleus (p > 0.05). However, the
EBD fluorescence intensity was significantly greater in the
interstitium of obese compared to lean EDL (p < 0.001)
and soleus (p < 0.005).
ROS-induced F2-isoprostane production
F2-isoprostane production was measured in EDL and so-
leus muscles. Lean Zucker rats contained 27% more F2-
isoprostanes compared to obese littermates in EDL (p <
0.05) (Figure 4A), and a similar trend in soleus (p = 0.07).
However the lower total arachidonic acid content in both
EDL (p < 0.01) and soleus (p < 0.05) muscles in obese com-
pared with lean samples (Figure 4B) indicated comparable
F2-isoprostane production when corrected for arachidonic
acid content (Figure 4C). Soleus muscle producedsignificantly more F2-isoprostanes compared to EDL (p <
0.05) for both groups of animals.
Calpain analyses
To determine if activation of Ca2+-mediated proteolytic
pathways are a mechanism involved in the muscle atro-
phy detected in obese Zucker rats, both μ-calpain and
calpain-3 autolysis were measured in EDL and soleus
(Figure 5). As shown by Western blot analyses (Figure 4B),
neither μ-calpain nor calpain-3 autolysis, and hence acti-
vation, were increased in obese rats compared to lean rats
in either EDL or soleus muscle.
Discussion
The obese Zucker rat is an established model of T2D
mellitus and displays the hallmark biochemical characteris-
tics of the disease including hyperinsulinemia, hypergly-
cemia and hyperlipidemia, in addition to insulin resistance,
as confirmed in this study and by others [33]. At the skel-
etal muscular level, atrophy is a well-documented conse-
quence of T2D [34,35]. This has been confirmed in the
current study, with a significant reduction in the muscle
weights of obese Zucker rats compared to lean controls,
accompanied by decreased fibre area in both fast- and
slow-twitch muscles. Muscular atrophy was observed
despite significantly increased body weights in the obese
group, in which the increased load-bearing of the
musculature should theoretically induce compensatory
hypertrophic adaptation to support the body weight.
We have investigated the hypothesis that diabetes-
associated muscular atrophy is resultant of an increased
susceptibility to myocellular damage – specifically due
to increased ROS-activated lipid peroxidation of the
sarcolemma, permeability of the sarcolemma to the
extracellular fluid and hyperactivation of the cytosolic
protease calpain. This study highlights that skeletal
muscle atrophy of fast and slow twitch fibres from the
obese Zucker rat is not directly associated with heightened
protein degradation due to physiological [Ca2+]-range cal-
pain activation, nor is it resultant of ROS-mediated lipid
peroxidation.
Impaired Ca2+ regulation has been reported to be an
influencing factor in the impaired muscle function and
morphology observed in T2D. Given this, [Ca2+]-activated
calpain autolysis was thought to be a likely mechanism in-
ducing the atrophy in obese muscle. While the direct
quantification of intracellular [Ca2+] and the Ca2+-handling
capacity of Zucker skeletal muscle is outside the scope of
this study, we have confirmed that any Ca2+ dysregulation
present is insufficient to induce autolysis of calpain-3 and/
or μ-calpain, both of which activate in the presence of
heightened [Ca2+] within physiological levels. It has been
documented that for calpain-3 to become activated, [Ca2+]i
of 200 nM for at least 60 min is required [13], whereas for
Figure 2 Skeletal muscle histology. (A) Average fibre area of skeletal muscle tissues (µm2). H & E stained skeletal muscle sections of EDL (B) and
soleus (C) of obese and lean rats. Magnification ×100. *p < 0.01 vs obese. #p < 0.01 vs EDL. n = 14 for each group.
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gests that neither of these [Ca2+]i ranges are being main-
tained for any sufficient period of time to induce sustained
calpain-activation and protein degradation to warrant the
observed muscle atrophy.
A common cause of persistently elevated [Ca2+]i, as
observed in many muscle pathologies, is sarcolemmal in-
stability which results in microtears within the phospho-
lipid structure and/or hyperactive stretch-induced leak
channel activity [36,37]. Using EBD as a marker of
muscle damage, we have demonstrated that sarcolemmal
integrity is maintained in skeletal muscle from obeserats, suggesting that (1) hyperglycemia and/or hyperin-
sulinemia do not directly cause instability and/or in-
creased permeability of the sarcolemma; and (2) that
muscle damage is not a cause of the observed atrophy.
When the sarcolemma is porous, albumin-conjugated
EBD can freely move into the muscle where it becomes
trapped, resulting in muscle fibres that fluoresce red
when viewed microscopically. While this study has dem-
onstrated a higher percentage of EBD fluorescence in
skeletal muscle cross-sections of obese rats, dye accumu-
lation was interestingly confined to the external mem-
brane/interstitium rather than being evenly distributed
Figure 3 EBD staining in muscle fibres of Zucker rats. Proportion (%) of cross-sectional area that is EBD+ (A). Average Fluorescence intensity
(arbitrary units) of EBD+ areas (B). Mean strength of EBD signal in myofibres and the interstitium as scored by a semi-quantitative Likert scale (C).
Muscle sections of EDL (D), and Soleus (E) of obese and lean rats showing EBD accumulation around the skeletal muscle membranes of obese
rats (solid arrows), with minimal penetration of the dye in lean rats. Magnification ×100. *p < 0.05 vs obese. #p < 0.05 vs EDL. n = 14 for each
animal group.
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tions of damaged skeletal muscle from the mdx mouse
model of Duchenne Muscular Dystrophy [32] – a severe
muscle wasting disease of which a feature is sarcolem-
mal instability and hyperactivation of Ca2+/calpain-in-
duced damage pathways. This demonstrates comparable
sarcolemmal integrity between sedentary obese Zucker
rats and lean controls, with no obvious signs of elevatedmuscle damage to the diabetic condition. To our know-
ledge, accumulation of EBD-conjugated albumin at the
extracellular sarcolemmal surface has not been reported
previously in diabetic skeletal muscle. We speculate that
this is reflective of increased extravasation of EBD-bound
albumin from associated capillaries [38] and subsequent
binding of albumin to membrane glycoproteins [39],
which are notably overexpressed on the extracellular
Figure 4 Isoprostane and arachidonic acid content of Zucker skeletal muscle. (A) Total muscle F2-isoprostane production per md tissue.
(B) Total muscle arachidonic acid content. (C) F2-isoprostane production corrected for arachidonic acid content. *p < 0.05 vs obese. **p < 0.01 vs
obese. #p < 0.05 vs EDL. ##p < 0.01 vs EDL. n = 13 for each group.
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Figure 5 Calpain activity of Zucker skeletal muscle. Percentage of activated Calpain-3 (A) and µ-Calpain (B). Western blots show either μ-Calpain
or Calpain-3 in obese and lean rats (C), with molecular mass markers, taken as a white light image prior to chemiluminescence and then images
superimposed, indicated on the left. n = 6 for all groups. *indicates the non-specific band seen in rodent skeletal muscle with this antibody.
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to a hyperglycaemic environment [40]. Excessive albu-
min accumulation demonstrably promotes modification
of the size and compilation of the interstitium [41], re-
duces membrane fluidity [42] and binds Ca2+e [43].
While such an effect may serve as a protective mechan-
ism to hyperglycaemia, how this would impact upon
normal skeletal muscle preservation and function is
currently unknown, although impaired nutrient diffu-
sion and reduced nutrient availability to ATP synthesis
could be a likely outcome.
ROS-induced F2-isoprostane production (measured as
a marker of lipid peroxidation) was hypothesised as an-
other potential mechanism responsible for the atrophy
found in the obese Zucker model of diabetes. Previous
research has demonstrated increased F2-isoprostanes in
plasma of patients with T2D [28]. However, our results
indicate that F2-isoprostane production was comparable
in both EDL and soleus muscle from obese compared to
lean rats. Isoprostane formation was significantly lower
(data not shown) in muscle from obese rats compared to
lean controls, however, so too was total arachidonic acid
content (data not shown). Thus, when corrected for total
arachidonic acid content, F2-isprostane production was
comparable between obese Zucker and control skeletal
muscle. This correction is essential given the reliance on
arachidonic acid availability for isoprostane production.
Whether this decrease in arachidonic acid content (and
thus isoprostane production) is reflective of prior sarco-
lemmal damage, or simply less capacity for production,
is unknown. As albumin has a tendency to bind to, and
stimulate, the release of arachidonic acid from the
membrane [42] and our EBD data demonstrates EBD-
conjugated albumin accumulation in the interstitial
space proximal to the extracellular sarcolemmal surface,
we speculate that albumin is having a direct effect on
the arachidonic acid content of the sarcolemma in obese
Zucker muscle. Low membrane arachidonic acid con-
tent, as has been demonstrated in the current study,
also reportedly reduces membrane fluidity [42]. How
changes to sarcolemmal fluidity effect normal skeletal
muscle preservation and function is currently unknown.
A notable limitation of our study is that we have in-
cluded only F2-isoprostane measurement as a marker of
lipid peroxidation – future research would benefit from
parallel analysis of lipid peroxidation byproducts such as
malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)
to enable complete assessment of membrane lipid damage.
Another interesting observation was that the predom-
inantly slow-twitch soleus muscle displayed a higher rate
of F2-isoprostane production than predominantly fast-
twitch EDL muscle. Although more glycolytic in nature,
Type II fibres are demonstrably more susceptible to oxida-
tive damage than Type I fibres. Since our soleus musclesections also had higher albumin-conjugated EBD fluores-
cence in the interstitium (likely due to their higher capil-
lary density [44]) comparative to glycolytic EDL sections,
we speculate that this albumin is actively binding to ara-
chidonic acid and releasing it from the sarcolemma [45].
This highlights that increased vascular permeability, and
in particular extravasation of albumin into the intersti-
tium, renders oxidative muscle fibres more susceptible to
membrane changes that may subsequently affect muscle
function.
Skeletal muscle mass is highly regulated by a variety of
molecular pathways that promote or inhibit protein syn-
thesis and degradation. While our data importantly dem-
onstrates that atrophy induced by the diabetic phenotype
is not linked to sarcolemmal porosity and the ensuing pro-
tein degradative pathways controlled by [Ca2+]i-induced
calpains, there are many other signaling mechanisms that
may be contributing to the atrogenic environment. Indeed,
the protein synthetic phosphatidylinositol 3-kinase (PI3K)/
phosphorylated Akt (pAkt) [46] and the protein degrada-
tive ubiquitin-proteasome proteolytic pathway [47] have
both been linked to T2D. The triggers that lead to activa-
tion of these pathways and subsequent alterations in pro-
tein turnover in T2D are still controversial, however our
data alongside others [4] suggests that inhibition of pro-
tein synthesis may be the overriding regulator. In addition
to impaired glucose uptake into skeletal muscle, insulin re-
sistance also reduces amino acid uptake [48] which may
explain the slower skeletal muscle protein synthesis rates
observed in this disease [4]. Paturi et al. [49] have con-
firmed reduced mTOR activation in skeletal muscle of
obese rats, which highlights that specifically targeting pro-
tein synthesis may be an effective way of reversing/pre-
venting the muscle atrophy observed in diabetic skeletal
muscles.
Conclusions
We have provided further evidence that obese Zucker
rat skeletal muscles are atrophic. The mechanisms are
demonstrably not related to sarcolemmal damage, pro-
tein degradation induced by heightened calpain activa-
tion or ROS-mediated lipid peroxidation. Additionally,
we have shown accumulation of albumin (as evidenced
by EBD fluorescence) on the extracellular surface of the
sarcolemma and interstitium which may be indicative of
capillary macromolecule extravasation – what effect this




A total of 42 rats were used in this study: 14-week-old
male obese Zucker and age-matched, non-diabetic lean
Zucker littermates (n = 7 for T2D biomarker experiments
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tane) served as the experimental and control groups, re-
spectively (Flinders University, Adelaide, Australia). Rats
of the same phenotype were housed in pairs and allowed
access to food and water ad libitum. All experiments were
approved by the Victoria University Animal Ethics Experi-
mentation Committee and conformed to the Australian
Code of Practice for the Care and Use of Animals for
Scientific Purposes.
Biochemical measures
While obese Zucker rats demonstrably develop insulin-
resistance by 14 weeks of age [33], we have quantified
plasma glucose and insulin concentrations and calcu-
lated insulin sensitivity to confirm T2D in our colony.
On a separate group of fasted (overnight) and anaethe-
tised rats (n = 7 for obese and lean groups), blood sam-
ples were collected via cardiac puncture into eppendorf
tubes and centrifuged (10 min at 13,300 RPM). Plasma
was decanted and immediately analysed for plasma glu-
cose using a Yellow Springs analyser (Yellow Springs
Instruments, Ohio, USA). Insulin concentration was de-
termined in 10 μl of plasma by ELISA according to the
protocol (Rat/Mouse Insulin ELISA Kit) provided by the
manufacturer (Linco Research). Using the derived plasma
glucose and insulin concentrations, insulin sensitivity
was calculated using the quantitative insulin sensitivity
check index (QUICKI) method (QUICKI = 1/[log(I0) +
log(G0)]) [50].
Muscle sampling protocol
Animals were injected with EBD as optimised for skeletal
muscle by Hamer et al. [32]. A 1% EBD solution (Ajax
Chemicals, 32688) (w/v) in phosphate-buffered saline
(PBS, pH 7.5), was filtered through a Millex-GP 0.22 μm
filter and stored at 4°C. Twenty four hours prior to muscle
sampling, rats were given an intraperitoneal (I.P.) injection
of 1% EBD (v/w). After the injection, animals were
returned to their cage and allowed access to food and
water ad libitum for 24 hours to allow optimal uptake
of the dye into any leaky myofibres [32].
On the day of muscle sampling, rats were weighed and
anaesthetised with Pentobarbitone Sodium (60 mg.kg−1
body weight). The Extensor Digitorum Longus (EDL,
fast-twitch), and Soleus (slow-twitch) muscles were ex-
cised, cleaned of excess fat and connective tissue, includ-
ing tendons, and weighed on standard laboratory scales.
The tissue collected was covered with Tissue-Tek and
frozen in isopentane cooled in liquid nitrogen for histo-
logical analyses of muscle membrane permeability, dam-
age and atrophy. EDL and soleus muscles from the
alternate leg were then removed, and snap frozen in li-
quid nitrogen for analysis of isoprostane production and
calpain activity.Muscle membrane permeability, damage and atrophy
Frozen embedded sections were cut (10 μm) at −21°C
on a cryostat, dipped in cold acetone (Merck) (−20°C)
for 1 min and air dried at room temperature. Sections
were then dipped into xylene (Merck) and mounted with
DPx (Fluka Biochemika) and a coverslip. Another slide
of consecutive serial sections was stained with Haemo-
toxylin and Eosin (H&E) to determine muscle fibre size.
In a single-blinded protocol, 100 fibres per section were
manually traced using Analytical Imaging Station (AIS)
software and the cross sectional area (μm2) of each fibre
was determined. The area analysed was chosen by pla-
cing the section in the centre of the field of vision at low
(40x) magnification, and then counting the fibres in view
when changing to the higher (100x) magnification.
EBD sections were visualised by fluorescence micros-
copy using a N2.1 green wavelength filter set (band pass =
515-560 nm; (low pass = 590 nm). The proportion of
cross-sectional area positive for EBD (EBD+) was deter-
mined and the fluorescence intensity (relative units) of
EBD+ areas was quantified. The location of EBD fluores-
cence intensity in the frozen sections was assessed semi-
quantitatively using a seven-point Likert scale scoring sys-
tem as per Hamer et al. [32]. The scale, from 0 to 6, was
defined as ranging from 0 = no signal; 1 =minimal signal;
2 = weak signal; 3 = good signal; 4 =moderate signal; 5 =
strong signal; 6 very strong signal. A score on this scale for
EBD red fluorescence was recorded for both myofibre
penetration and the interstitium, viewed at a final magnifi-
cation of 100x. H&E sections were viewed with light mi-
croscopy (Zeiss Axiolab, Carl Zeiss GmbH)
ROS-induced F2-isoprostane production
Tissue F2-isoprostanes were measured as previously de-
scribed [51]. F2-isoprostanes were detected by electron-
capture negative ionization GC-MS after solid-phase ex-
traction and corrected for total arachidonic acid content.
Arachidonic acid was measured in lipid extracts from
frozen muscle, after conversion to the methyl esters with
2 mL 4% H2SO4 in methanol (90 C, 10 min). The methyl
esters of fatty acids were analysed by gas chromatog-
raphy as previously described [34]. Heptadecanoic acid
(50 μL of stock 1 mg/mL) was used as internal standard.
Calpain analyses
μ-calpain and calpain-3 autolysis was determined in
skeletal muscle from obese (n = 6) and lean (n = 6) rats.
Muscle samples were homogenised using 10 volumes of
ice-cold extraction buffer, comprising 0.4 M Tris-Cl,
pH 6.8, and 25 mM EGTA ([Ca2+] < 10 mM). SDS was
added to a final concentration of 4%. Muscle homogenates
were incubated at 4°C for 20-40 min, an aliquot was kept
for protein concentration assay (Quant-iT fluorescence
assay, Invitrogen), and the remaining homogenate was
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SDS loading buffer (2:1 v/v) comprising of 0.125 M Tris
HCl, 10% glycerol, 4% SDS, 4 M urea, 10% mercaptoetha-
nol, and 0.001% bromophenol blue, pH 6.8 which had
been diluted (2:1 v/v) in physiological based solution. Sam-
ples were stored at −20°C until analysis. Samples were
analysed by Western blotting as previously described [13].
Total protein from muscle samples were separated on an
8% SDS-PAGE gel and transferred to nitrocellulose
membranes. The membranes were probed with anti-
bodies against μ-Calpain (1:1,000 mouse monoclonal,
Sigma monoclonal, clone 15C10), and calpain-3 (1:200
mouse monoclonal, Novocastra monoclonal 12A2), and
goat anti-mouse horseradish peroxidise (HRP) (1:50,000
Bio-Rad) was then added to the membranes. Bands were
visualised with West Pico chemiluminescent substrate
(Pierce), and densitometry was completed using Quantity
One software (Bio-Rad). Once transferred, gels were
stained with BioSafe Coomassie blue (Bio-Rad), and my-
osin heavy chain (MHC) in the post-transferred gel as well
as membranes probed with actin (Sigma A-2066) were
used as an indicator of sample loaded [16]. Full-length
μ-calpain was visualised as an 80 kDa protein, and its acti-
vation was confirmed by its autolysis to 78- and 76-kDa
proteins. Calpain-3 was observed as a 94-kDa protein with
activation confirmed by autolysis to proteins of approxi-
mately 60-, 58-, and 55-kDa [14]. Data for the Western
blots are presented as the density of the bands corre-
sponding to the autolysed products relative to the density
of the total bands representing μ-calpain or calpain-3 for a
given sample. This indicated the proportion of μ-calpain
or calpain-3 that was autolysed in a particular sample, irre-
spective of any minor differences in protein loading.Data analyses
Results are expressed as means ± Standard Error of
Mean (SEM) and compared by two-way ANOVA, with
animal strain and muscle type as factors. No significant
interactions were detected. In all cases a P < 0.05 was
considered statistically significant.
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